PubRank

Wafik S El-Deiry

Author PubWeight™ 212.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Overview of cell death signaling pathways. Cancer Biol Ther 2005 4.22
3 Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007 3.37
4 Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006 2.96
5 TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003 2.75
6 P53 and radiation responses. Oncogene 2003 2.52
7 Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell 2009 2.30
8 The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev 2007 2.16
9 Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013 2.06
10 p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013 2.06
11 Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2003 1.92
12 Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004 1.90
13 Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 2006 1.88
14 BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002 1.84
15 Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 2003 1.83
16 Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A 2006 1.80
17 Tissue-specific induction of p53 targets in vivo. Cancer Res 2002 1.79
18 TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010 1.65
19 Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 2004 1.59
20 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007 1.58
21 CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol 2008 1.58
22 DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005 1.55
23 Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004 1.54
24 Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol 2003 1.54
25 Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008 1.52
26 The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle 2002 1.45
27 Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget 2011 1.43
28 Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther 2009 1.43
29 TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008 1.41
30 Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008 1.41
31 Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009 1.40
32 Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 2005 1.38
33 Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther 2004 1.38
34 TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008 1.34
35 Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther 2003 1.32
36 Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res 2009 1.31
37 Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A 2002 1.30
38 Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004 1.29
39 Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004 1.28
40 BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002 1.28
41 Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle 2007 1.28
42 Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 2005 1.27
43 Current strategies to target p53 in cancer. Biochem Pharmacol 2010 1.26
44 Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008 1.25
45 Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003 1.25
46 Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002 1.24
47 Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003 1.24
48 Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem 2011 1.23
49 An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics 2012 1.22
50 Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004 1.22
51 Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007 1.22
52 Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep 2010 1.21
53 Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res 2006 1.20
54 The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009 1.18
55 ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest 2014 1.16
56 Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther 2006 1.16
57 Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003 1.16
58 What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther 2006 1.16
59 ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle 2015 1.14
60 Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 2003 1.14
61 Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 2003 1.13
62 Regulation of the human TRAIL gene. Cancer Biol Ther 2012 1.12
63 Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002 1.12
64 Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A 2004 1.10
65 p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 2006 1.09
66 Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol 2008 1.08
67 Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 2011 1.07
68 Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther 2005 1.04
69 ERK and MDM2 prey on FOXO3a. Nat Cell Biol 2008 1.04
70 Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013 1.03
71 Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res 2013 1.02
72 Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005 1.02
73 Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol Ther 2003 1.02
74 Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol 2004 1.02
75 Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets 2015 1.02
76 p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab 2005 1.01
77 Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets 2012 1.01
78 CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem 2006 1.01
79 TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008 1.01
80 BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem 2003 1.00
81 Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011 0.99
82 Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007 0.99
83 CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 2013 0.98
84 Multispectral fluorescence imaging. J Nucl Med 2009 0.98
85 Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 2002 0.98
86 IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther 2007 0.97
87 Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther 2003 0.97
88 The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle 2011 0.97
89 Clinical implication of p53 mutation in lung cancer. Mol Biotechnol 2003 0.96
90 p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol 2007 0.96
91 Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem 2003 0.96
92 Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol Ther 2006 0.95
93 Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res 2011 0.94
94 Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther 2011 0.94
95 Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget 2014 0.94
96 Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 2008 0.93
97 DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 2008 0.93
98 Targeting p53 by PTD-mediated transduction. Trends Biotechnol 2004 0.93
99 Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther 2011 0.93
100 Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008 0.93
101 EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol 2005 0.92
102 TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells. Cancer Res 2008 0.92
103 Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem 2013 0.92
104 Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol 2003 0.92
105 Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012 0.92
106 Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73beta. Oncogene 2003 0.91
107 Childhood ALL and second neoplasms. Cancer Biol Ther 2007 0.91
108 Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One 2013 0.91
109 Hyperspectral image analysis of live cells in various cell cycle stages. Cell Cycle 2007 0.90
110 Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol Ther 2009 0.90
111 Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther 2005 0.89
112 IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 2002 0.89
113 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther 2009 0.89
114 The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 2009 0.89
115 Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther 2009 0.89
116 Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle 2012 0.89
117 Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther 2011 0.88
118 Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 2007 0.88
119 Derangement of growth and differentiation control in oncogenesis. Bioessays 2002 0.88
120 Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle 2013 0.88
121 Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 2007 0.87
122 Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 2008 0.87
123 Glucocorticoid-induced tumor necrosis factor receptor is a p21Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. J Biol Chem 2005 0.87
124 Structure-based design of p18INK4c proteins with increased thermodynamic stability and cell cycle inhibitory activity. J Biol Chem 2002 0.86
125 Identification and characterization of proteins interacting with Traf4, an enigmatic p53 target. Cancer Biol Ther 2006 0.86
126 Circulating tumor cell isolation during resection of colorectal cancer lung and liver metastases: a prospective trial with different detection techniques. Cancer Biol Ther 2015 0.85
127 Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology 2011 0.85
128 Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011 0.85
129 CARPs enhance p53 turnover by degrading 14-3-3sigma and stabilizing MDM2. Cell Cycle 2008 0.84
130 Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biol Ther 2005 0.84
131 Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo. Cancer Biol Ther 2008 0.84
132 Crystal structure of a FYVE-type zinc finger domain from the caspase regulator CARP2. Structure 2004 0.84
133 The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res 2004 0.83
134 Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol Ther 2005 0.82
135 Cell death: a new Par-4 the TRAIL. Cell 2009 0.82
136 Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation. Cancer Biol Ther 2015 0.82
137 Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biol Ther 2015 0.81
138 FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol 2011 0.81
139 Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biol Ther 2011 0.81
140 Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013 0.81
141 High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol 2011 0.81
142 Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res 2003 0.81
143 Novel antineoplastics targeting genetic changes in colorectal cancer. Adv Exp Med Biol 2013 0.81
144 Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL. Cancer Biol Ther 2005 0.81
145 Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin Cancer Res 2006 0.81
146 Multimodality optical imaging and 18F-FDG uptake in wild-type p53-containing and p53-null human colon tumor xenografts. Cancer Biol Ther 2007 0.80
147 p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther 2004 0.80
148 Calcein-effluxing human colon cancer cells are enriched for self-renewal capacity and depend on β-catenin. Oncotarget 2013 0.80
149 p53-dependent induction of serine proteases in irradiated mouse colon. Cancer Biol Ther 2004 0.79
150 Regulation of the p53 homolog p73 by adenoviral oncogene E1A. J Biol Chem 2003 0.79
151 Cytochrome c: a crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis. Cancer Biol Ther 2004 0.79
152 Zebrafish: swimming towards a role for fanconi genes in DNA repair. Cancer Biol Ther 2004 0.79
153 p53-induced gene expression analysis. Methods Mol Biol 2003 0.79
154 Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: implications for monitoring angiogenesis. Cancer Biol Ther 2007 0.79
155 The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PLoS One 2013 0.78
156 Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. Cancer Biol Ther 2013 0.78
157 CARPs are E3 ligases that target apical caspases and p53. Cancer Biol Ther 2007 0.78
158 Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther 2012 0.78
159 Targeting FOXO kills two birds with one stone. Chem Biol 2004 0.78
160 Studying p53-dependent cell death in vitro and in vivo. Methods Enzymol 2008 0.78
161 Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. Methods Mol Biol 2003 0.78
162 Taming NEMO to slay cancer cells. Cancer Biol Ther 2006 0.77
163 Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. Oncoimmunology 2012 0.77
164 Impact of genetic targets on cancer therapy. Forward. Adv Exp Med Biol 2013 0.77
165 Detection of DSS-induced gastrointestinal mucositis in mice by non-invasive optical near-infrared (NIR) imaging of cathepsin activity. Cancer Biol Ther 2013 0.77
166 CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle 2012 0.77
167 Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction. Cancer Biol Ther 2011 0.76
168 The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J 2006 0.76
169 FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013 0.76
170 The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo. Cell Cycle 2013 0.75
171 A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. Cancer Biol Ther 2015 0.75
172 Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS One 2016 0.75
173 Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biol Ther 2015 0.75
174 4th international conference on tumor progression and therapeutic resistance: meeting report. Cancer Biol Ther 2015 0.75
175 Analysis of cyclin-dependent kinase activity. Methods Mol Biol 2003 0.75
176 Plagiarism is not acceptable in science or for cancer biology & therapy. Cancer Biol Ther 2005 0.75
177 COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. Cancer Res 2014 0.75
178 Flow cytometric analysis of cell cycle control by tumor suppressor genes. Methods Mol Biol 2003 0.75
179 Funding the marathon: investigators need more than basic experiments and clinical trials to advance the war on cancer. Cancer Biol Ther 2010 0.75
180 DNA footprinting. Methods Mol Biol 2003 0.75
181 Novel and Emerging Targeted Therapies of Colorectal Cancer. Curr Clin Pharmacol 2015 0.75
182 Flow cytometric analysis of tumor suppressor gene-induced apoptosis. Methods Mol Biol 2003 0.75
183 Yeast two-hybrid screening as a means of deciphering tumor suppressor pathways. Methods Mol Biol 2003 0.75